HC Wainwright Has Bearish Forecast for VNDA Q4 Earnings

Key Points

• HC Wainwright has lowered its Q4 2026 EPS estimate for Vanda Pharmaceuticals to $0.12 from $0.13, maintaining a "Buy" rating and a target price of $20.00.
• Vanda recently reported a Q2 EPS of ($0.46), falling short of expectations, alongside revenue of $52.59 million against a forecast of $54.77 million.
• Insider trading activity includes Director Stephen Ray Mitchell selling 7,000 shares while CEO Mihael Hristos Polymeropoulos purchased 10,000 shares, indicating differing confidence levels among company leaders.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) - Analysts at HC Wainwright reduced their Q4 2026 EPS estimates for Vanda Pharmaceuticals in a research note issued to investors on Tuesday, August 12th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings of $0.12 per share for the quarter, down from their prior forecast of $0.13. HC Wainwright currently has a "Buy" rating and a $20.00 target price on the stock. The consensus estimate for Vanda Pharmaceuticals' current full-year earnings is ($1.12) per share.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.12). The company had revenue of $52.59 million for the quarter, compared to analysts' expectations of $54.77 million. Vanda Pharmaceuticals had a negative return on equity of 12.89% and a negative net margin of 32.90%.

VNDA has been the subject of several other research reports. Wall Street Zen cut shares of Vanda Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Saturday, August 2nd. Cantor Fitzgerald reiterated an "overweight" rating and set a $13.00 target price on shares of Vanda Pharmaceuticals in a report on Wednesday, May 14th.

Vanda Pharmaceuticals Stock Up 2.0%

VNDA stock opened at $4.40 on Wednesday. Vanda Pharmaceuticals has a 52 week low of $3.81 and a 52 week high of $5.55. The stock has a market capitalization of $259.70 million, a P/E ratio of -3.89 and a beta of 0.72. The firm has a 50-day simple moving average of $4.62 and a 200-day simple moving average of $4.53.

Insider Activity

In related news, Director Stephen Ray Mitchell sold 7,000 shares of the firm's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $4.59, for a total value of $32,130.00. Following the completion of the sale, the director owned 97,082 shares in the company, valued at $445,606.38. This trade represents a 6.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Wednesday, May 21st. The stock was bought at an average price of $4.40 per share, with a total value of $44,000.00. Following the purchase, the chief executive officer directly owned 2,325,731 shares of the company's stock, valued at approximately $10,233,216.40. This trade represents a 0.43% increase in their ownership of the stock. The disclosure for this purchase can be found here. 8.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Vanda Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VNDA. CWM LLC raised its position in Vanda Pharmaceuticals by 424.6% during the second quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company's stock worth $44,000 after acquiring an additional 7,575 shares during the last quarter. Quantinno Capital Management LP acquired a new position in Vanda Pharmaceuticals during the fourth quarter worth about $48,000. PVG Asset Management Corp acquired a new position in Vanda Pharmaceuticals during the first quarter worth about $48,000. Linden Thomas Advisory Services LLC purchased a new stake in shares of Vanda Pharmaceuticals during the first quarter worth about $49,000. Finally, Nations Financial Group Inc. IA ADV purchased a new stake in shares of Vanda Pharmaceuticals during the first quarter worth about $67,000. Institutional investors and hedge funds own 88.14% of the company's stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.